Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches
{{output}}
Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers a uniquely comprehensive and integrative perspective on... ...
